Pharma is suddenly a high-conviction theme again. Between weight-loss drugs, oncology blockbusters and a more friendly UK research environment, the world's biggest healthcare names are back on every UK investor's watchlist.

Pharma stops being boring

For most of the 2010s, big pharmaceuticals were the definition of a defensive holding: steady, slightly dull, occasionally disrupted by a Patent cliff or a regulatory scare. Investors held them because they paid dividends and didn't crash too hard during recessions, not because they were exciting. That has changed sharply in the past three years. The arrival of GLP-1 agonists for obesity, the maturation of precision oncology, the boom in messenger RNA platforms and the steady cash generation of medical-devices arms have together turned healthcare into one of the most discussed sectors in the world.

For UK investors, the story has an added local dimension. AstraZeneca is now the largest company in the FTSE 100 by Market Value on most measures, and it has anchored the UK index's outperformance against several European peers since the Pandemic. Globally, the conversation has been dominated by Eli Lilly and Novo Nordisk, two of the most spectacular share-price stories of the past decade thanks to their dominance of the GLP-1 category. Roche and Johnson &Amp; Johnson, more diversified and somewhat slower-moving, complete a picture of a sector that has plenty going on under the bonnet.

We will stick to figures from our supplied data sheet for valuation context, look at what is actually driving each Business, and try to be balanced about both the opportunities and the very real risks involved in owning these names. Importantly, while the headlines will keep coming about new launches and clinical readouts, the underlying investor question is unchanged: which of these companies can compound Earnings reliably over the next decade?

The numbers behind the headline names

AstraZeneca, the FTSE 100 heavyweight, trades at 13,512p on our sheet, in a 52-week range of 9,651p to 15,732p. It is on a 27.89 P/E with a 1.79% Yield and a market value of £209.57bn. That valuation reflects what has been a transformation under the current Leadership: an oncology-led pipeline, a strong rare-disease Franchise, and a respiratory and cardiovascular and metabolic portfolio that throws off serious cash. The company has become one of London's clearest examples of a UK-listed business with genuinely global scale.

Eli Lilly is the GLP-1 darling. On our data, it trades at 934.60, in a 52-week range of 623.78 to 1,133.95, on a 40.63 P/E and a 0.74% yield, with a market value of 883.03b. The Valuation Premium is enormous compared with traditional pharma multiples, and reflects the structural change investors believe weight-loss therapies will bring to the company's Revenue base over the coming decade. The price action has not been one-way; the 52-week range alone shows a swing of more than 80% from low to high.

Novo Nordisk is the original GLP-1 story. Trading at DKK 272.25 in our sheet, with a 52-week range of DKK 224.25 to DKK 533.40, on an 11.81 P/E and a 4.30% yield, with a market value of DKK 922.96bn, it presents a very different profile from Lilly. The fall from the 52-week high to a level closer to the low looks dramatic, and reflects investor concern about competitive pressure and clinical-trial readouts. The flip side is that, on these figures, Novo trades at a markedly more modest multiple than Lilly.

Johnson & Johnson, the diversified US healthcare conglomerate, comes in at 229.85, with a 52-week range of 146.12 to 251.71, on a 26.33 P/E and a 2.33% yield, capitalised at 553.30b. After the spin-off of its consumer division, J&J is now a pure pharmaceuticals and medical-devices business, and the Dividend record remains one of the longest and most reliable in global Equity markets.

Roche, the Swiss pharmaceuticals heavyweight, trades at CHF 326.60 on our sheet, with a 52-week range of CHF 256.40 to CHF 383.00, a 20.19 P/E, a 3.00% yield and a market value of CHF 34.85bn. Roche has spent the past few years rebuilding investor confidence after the Covid-era diagnostics boom unwound, and its oncology franchise, neurology pipeline and continued strength in diagnostics make it a more diversified pick than the GLP-1 specialists. It also throws off a meaningful dividend, which appeals to income-oriented investors looking for healthcare exposure outside the higher-multiple US names.

Why investors are paying attention now

Three forces are pushing healthcare back to the front of investor inboxes. The first is demographics. The world is, unmistakably, getting older. Populations across the United States, Europe, China and Japan are ageing rapidly, and chronic conditions, from cardiovascular disease to dementia, are absorbing an ever larger share of healthcare spending. That demographic backdrop underwrites the long-term revenue base of companies that Supply drugs, devices and diagnostics for the elderly.

The second is the obesity revolution. GLP-1 agonists, originally developed for type 2 diabetes, have turned out to be remarkably effective treatments for obesity, and emerging evidence suggests benefits in cardiovascular disease, sleep apnoea and other related conditions. Eli Lilly and Novo Nordisk have effectively created a new category overnight. Whether the maths supports current expectations depends on adherence rates, pricing, Manufacturing capacity and competition from oral GLP-1s and next-generation molecules.

The third is the pace of scientific progress. Antibody-drug conjugates, bispecifics, mRNA platforms, gene therapies and a growing list of precision oncology approaches mean that pharma's Research and Development engine is producing more meaningful innovation than at any time in recent memory. Roche and AstraZeneca have notably leaned into oncology innovation, while Johnson & Johnson has spent heavily on autoimmune and neuroscience platforms. For investors, that translates into a pipeline of potential new products that could replace older, increasingly genericised revenue streams.

What is driving each business

AstraZeneca's growth is underpinned by oncology, where it has built one of the most respected late-stage pipelines in the industry. The company's respiratory franchise, including Biologics for severe asthma, and a growing rare-disease portfolio inherited from its Alexion Acquisition, give it a degree of Diversification that some of its peers lack. Investor attention in 2026 is split between the pace of oncology launches and the read-through from major late-stage clinical trial readouts. Management has continued to set ambitious medium-term revenue targets, and the share price has tended to trade in step with how plausible those numbers feel from one quarter to the next.

Eli Lilly's near-term story is dominated by tirzepatide, used in both diabetes and obesity. Capacity constraints have, for now, been a feature rather than a bug, with the company expanding its manufacturing footprint aggressively. Beyond GLP-1s, Lilly has a respected Alzheimer's franchise, a strong oncology pipeline and an immunology arm. The 40.63 P/E in our data reflects expectations that the GLP-1 franchise becomes meaningfully larger from here. A premium of that size leaves little room for execution missteps but does come with one of the most exciting growth profiles in global large-cap equity markets.

Novo Nordisk has the deepest GLP-1 heritage and remains one of two genuine global leaders in the category. The drop in the share price from its high reflects competitive pressures, but the company continues to invest heavily in next-generation molecules, including oral GLP-1s and combination therapies. Its 4.30% yield is unusual in the high-growth pharma cohort and gives it a slightly different flavour for income-focused investors. The combination of a relatively modest 11.81 P/E and a chunky yield arguably makes it one of the more interesting risk-reward setups in big pharma, provided the next wave of clinical data lives up to expectations.

Johnson & Johnson's diversification across pharmaceuticals, medical devices and orthopaedics gives it less explosive growth than the GLP-1 names but a more predictable revenue stream. Its medical-devices arm benefits from strong procedure volumes following the post-pandemic Backlog clearing, while its pharmaceutical pipeline continues to invest in oncology and immunology. Roche, meanwhile, leans on a global oncology business, a continuing diagnostics franchise and an increasingly important neurology pipeline. Both companies offer the kind of slow-and-steady growth that can anchor a defensive sleeve of a portfolio, particularly during periods when more speculative healthcare names are giving back gains.

Risks that healthcare investors keep underestimating

The first risk is patent cliffs. Big pharma is a serial victim of expiring exclusivity, and even the most diversified companies have to keep replacing revenue from drugs that lose patent protection. AstraZeneca, Roche and Johnson & Johnson all face known cliffs over the next several years, and investor sentiment can swing sharply when launch trajectories of replacement products fall short.

The second is pricing pressure. Drug pricing remains a politically charged topic in the United States, with Medicare negotiation under the Inflation Reduction Act now beginning to bite on selected products. In Europe, including the UK, regulators continue to push back on prices through health-technology assessment processes. Even successful drugs can Fail to meet investor revenue expectations because reimbursement comes in lower than hoped.

Third, GLP-1 specifically faces real competitive risk. Eli Lilly and Novo Nordisk currently dominate the category, but a long list of competitors are working on next-generation injectables, oral formulations and combination products. As prescription volumes rise, payors will inevitably push back on pricing, and competitive intensity will rise. The dramatic 52-week range on Novo Nordisk in our data reflects exactly this kind of investor wobble.

Fourth, regulatory and clinical-trial risk is permanent. Even at the size of Johnson & Johnson or Roche, a single late-stage trial failure can wipe out billions of pounds of value in an afternoon. For more concentrated names, a setback on a flagship asset can be existential. Investors looking at high-multiple pharma should be honest with themselves about how they would react to a 20% gap-down.

Finally, there is the political risk to UK-listed exposure. AstraZeneca's relationship with the UK government, NHS pricing dynamics and corporate-tax considerations have all been topics of public discussion in recent months. None of these risks is a deal-breaker, but they should be factored into any investor's mental model.

A balanced takeaway for UK investors

Healthcare is one of the few sectors that genuinely has it all in 2026: large addressable markets, demographic tailwinds, real innovation, dependable cash generation and a mix of high-growth and dividend-paying names. AstraZeneca offers UK investors a domestic listing on a globally significant company; Eli Lilly and Novo Nordisk give two routes into the GLP-1 story at different valuations; Johnson & Johnson and Roche provide more diversified, slower-moving exposure with a respectable dividend stream.

A sensible portfolio approach is to think about diversification within the sector itself: pairing one or two GLP-1-exposed names with a more diversified pharma or healthcare conglomerate, and possibly a medical-devices or diagnostics leg. UK investors with home-bias considerations may also choose to anchor their healthcare exposure with AstraZeneca and complement it with overseas names through funds or directly. Currency exposure across the dollar, euro, Swiss franc and Danish krone should be considered alongside the underlying business mix.

Above all, healthcare is a long-game industry. Drug pipelines unfold over years, regulatory pathways are long, and reimbursement decisions can take longer than investors expect. The companies above are not without risk, but for investors with a multi-year horizon they offer some of the cleanest exposure to the demographic and innovation tailwinds reshaping the global economy. Anchoring positions to fundamentals, rather than to the latest swing in clinical-trial sentiment, is the discipline that has historically separated long-term winners in the sector from short-term traders.